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Abstract
 
The bacterial toxin protein A from 
 
Staphylococcus aureus
 
 (SpA) interacts with B cell antigen re-
ceptors encoded by variable region heavy chain (V
 
H
 
) clan III genes via a V region framework
surface that has been highly conserved during the evolution of the adaptive immune system. We
have investigated the consequences of exposure to this prototypic B cell superantigen, and
found that treatment of neonates or adults induces a T cell–independent deletion of a large supra-
clonal set of susceptible B cells that includes clan III/V
 
H
 
 S107 family–expressing lymphocytes.
In studies of different SpA forms, the magnitude of the induced deletion directly correlated with
the V
 
H
 
-specific binding affinity/avidity. Upon cessation of SpA exposure, the representation of
conventional splenic (B-2 subset) lymphocytes normalized; however, we found that the V
 
H
 
family–restricted deficit of peritoneal B-1 cells persisted. SpA treatment also induced a persistent
loss of splenic S107-
 
m
 
 transcripts, with a loss of certain natural antibodies and specific tolerance
to phosphorylcholine immunogens that normally recruit protective antimicrobial responses
dominated by the S107-expressing B-1 clone, T15. These studies illustrate how a B cell super-
antigen can exploit a primordial Achilles heel in the immune system, for which B-1 cells, an im-
portant source of natural antibodies and host immune responses, have special susceptibility.
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Introduction
 
Superantigens (SAgs)
 
1
 
 are products of microbial pathogens
that have the capacity to adversely affect immune respon-
siveness by interactions with highly represented conserved
sites in the V regions of the antigen receptors of host lym-
phocytes. These proteins have been studied to elucidate
their possible roles in pathogenesis of inflammatory and au-
toimmune diseases, and these nonimmune binding interac-
tions have also provided an invaluable window into the sig-
naling, cytokine, and cognate parameters of T lymphocyte
antigen receptor (TCR)-mediated stimulation. Analogous
in vitro interactions of several naturally occurring proteins
with B cell antigen receptors (BCRs) have also been de-
scribed (for a review, see reference 1); however the impli-
cations for in vivo exposure to a B cell SAg are largely un-
explored.
Of all putative B cell SAgs, protein A of 
 
Staphylococcus
aureus
 
 (SpA) has been the best characterized. Despite the
fact that this 42-kD secreted membrane protein does not
appear to play an essential role in the metabolism or sur-
vival of the bacterium, SpA is produced by most (or all)
clinical isolates (2). Consequently, it has been postulated
that the highly refined Ig binding properties of SpA
evolved to play a role in the host–pathogen relationship.
Staphylococcal virulence has been shown to be enhanced
by SpA in experimental models (3) but the responsible
pathophysiologic mechanism(s) have not been determined.
The immunomodulatory activities of SpA are likely
aided by its oligovalent organization. It is composed of five
56–61-amino acid homologous extramembrane domains in
tandem (4), and each domain possesses both the well-
known Fc
 
g
 
 binding specificity and a separate binding site
that is specific for Fab-containing V
 
H 
 
regions from the
structurally related clan III families (5, 6). Furthermore, in
vitro stimulation with 
 
S. aureus
 
 has been reported to prefer-
 
Address correspondence to Gregg J. Silverman, University of California at
San Diego, 9500 Gilman Dr., La Jolla, CA 92093-0663. Phone: 858-534-
5439; Fax: 858-534-5399; E-mail: gsilverman@ucsd.edu
 
1
 
Abbreviations used in this paper:
 
 BCR, B cell antigen receptor; C-PS,
pneumococcal cell wall polysaccharide;
 
 
 
FR, framework; GAPDH, glyc-
eraldehyde 3-phosphate dehydrogenase; HEL, hen egg lysozyme; HRP,
horseradish peroxidase; ISC, IgM-secreting cell; MSpA, chemically mod-
ified SpA; PC, phosphorylcholine; PerCP, peridinin chlorophyll protein;
RT, reverse transcription; SAg, superantigen; SpA, 
 
Staphylococcus aureus
 
protein A; TI-2, thymus-independent type 2. 
88
 
B Cell Superantigen–induced “Hole” in the B-1 Repertoire
 
entially select for human B cells expressing genes from the
V
 
H
 
3 family (7).
The special molecular features of the Fab-binding speci-
ficity of SpA, which were first identified in correlation with
antibody sequence usage (1, 8, 9), have recently been eluci-
dated in crystallographic analyses of a human IgM Fab–SpA
domain cocomplex. This interaction was shown to be me-
diated by a clan III–restricted surface, distant from the
CDR loops responsible for the recognition of conventional
antigens (10), which involves 13 contact residues in the V
 
H
 
framework (FR)1 and FR3 subdomains that have been
conserved during the evolution of the adaptive immune
system (11, 12). As a direct consequence, this unconven-
tional type of V
 
H
 
-restricted BCR-mediated binding activ-
ity is highly represented in immune systems of diverse
mammalian species, including the human system in which
the V
 
H
 
3 family of clan III composes nearly half of all inher-
ited V
 
H
 
 genes. It is also prevalent in amphibian and avian
species that have been studied (12). In the mouse, the ho-
mologous clan III families S107, J606, 7183, and DNA4
commonly convey this binding activity although the affini-
ties of these interactions vary (12–14).
In a recent report, we showed that 
 
.
 
5% of mature B
cells in naive BALB/c mice possess this nonimmune bind-
ing activity, and it is also displayed by 
 
z
 
12% of constitu-
tively IgM-secreting splenic cells and a comparable propor-
tion of circulating natural IgM (15). Most importantly, we
found that neonatal exposure to a chemically modified
form of SpA that is devoid of Fc-binding activity induced
an acute loss of 
 
.
 
80% of SpA-reactive splenic B cells. Al-
though this cellular representation in the spleen later nor-
malized, there was still a long-lasting loss of SpA-reactive
IgM-secreting cells (ISCs) and an equivalent loss of circu-
lating SpA-reactive IgM, which persisted, despite the pres-
ence of SpA-specific T cells, when evaluated 
 
.
 
1 yr later
(15). However, these studies did not identify which B cells
are susceptible to SAg-mediated deletion, and the implica-
tions for host immune responsiveness were not further
considered.
We have now investigated the molecular and cellular
mechanisms responsible for the immunomodulatory activi-
ties of this model B cell SAg. To determine the functional
features responsible for its immunological properties, we
have compared the host’s response to native SpA to treat-
ment with several forms of SpA that vary in their Fc- and
Fab-binding activities. Within these studies, we have also
identified the V
 
H
 
-defined supraclonal B cell set most af-
fected by treatment. Moreover, we found that SpA expo-
sure adversely affected the levels of certain natural antibod-
ies and caused a selective tolerance to immunogens
important for host defense against many bacterial as well as
protozoan, fungal, and nematode pathogens (16). Based on
these findings, we present a model explaining how this mi-
crobial toxin can cause an immunosuppression in the host
B cell compartment based on V
 
H
 
 usage, and discuss why B-1
cells are especially susceptible to the induction of long-
lasting effects.
 
Materials and Methods
 
Mutagenesis and Cloning of Domain D
 
9
 
 Derivatives.
 
To create
novel recombinant forms of SpA, the L17D and I31A mutations
(17) were introduced into the gene for domain D (DD
 
9
 
) of SpA
in the pDomD
 
9
 
 plasmid (5), and termed mDomD
 
9
 
. By overlap
PCR methods, a two domain product, dimeric mDD
 
9
 
(dimDD
 
9
 
), and four domain product, tetra-mutant domainD
 
9
 
(tetmDD
 
9
 
), were created in the pRSET system (Invitrogen) (Sil-
verman, G.J., manuscript in preparation).
 
Mice and Immunogens.
 
Mice were obtained from The Jackson
Laboratory and bred under specific pathogen-free conditions un-
der the supervision of the University of California San Diego An-
imal Subjects Program. Applying a previously reported protocol
(15), beginning within 24 h of birth mice were treated with ei-
ther hen egg lysozyme (HEL; Sigma-Aldrich), OVA (Sigma-
Aldrich), tetmDomD
 
9
 
, domain D
 
9
 
, rSpA (Repligen), or SpA that
was iodinated (MSpA) to selectively ablate Fc-binding activity
(18, 19), which had been purified to remove endotoxin. These
neonatal mice received PBS or 100 
 
m
 
g of protein in PBS, intra-
peritoneally every other day for the first 2 wk of life (eight doses of
100 
 
m
 
g protein). Adult mice, at least 6 wk of age, received 1 mg
of protein every other day for five doses. In all experiments, mice
were age and sex matched.
To assess immune responsiveness, certain groups of BALB/c 
 
3
 
C57BL/6 F1 mice were challenged with the phosphorylcholine
(PC)-KLH conjugate (50 
 
m
 
g/dose; Biosearch Technologies),
whereas others received the thymus-independent type 2 (TI-2)
immunogens of B1355 dextran (50 
 
m
 
g/dose; gift of Norman
Klinman, The Scripps Research Institute, La Jolla, CA) or pro-
nase-treated extract of 10
 
8
 
 CFU of heat-killed R36A
 
 Streptococcus
pneumoniae
 
 (gift of David Briles, University of Alabama at Bir-
mingham, Birmingham, AL) in CFA (Difco). Alternatively, mice
were challenged intravenously with 2 
 
m
 
g of pneumococcal cell
wall polysaccharide (C-PS; Serumstaatinstitut) in saline. Blood
was collected 10 d later for serologic assays, as described (15).
 
Immunoassays of Antibody Responses.
 
The antibody response
to MSpA and control antigens was quantified as described previ-
ously (15). In brief, microtiter wells were coated overnight with
protein, dextran, or C-PS at 5 
 
m
 
g/ml in PBS. After blocking
with 2% BSA/PBS, serum samples diluted in block were incu-
bated for 4 h at room temperature. The amount of bound anti-
body was determined by incubation with horseradish peroxidase
(HRP)-labeled affinity-purified goat F(ab
 
9
 
)
 
2 
 
anti–mouse Ig-,
IgM-, IgG-, or IgG subclass–specific reagents (Jackson Immu-
noResearch Laboratories), with values obtained after incubation
of substrate for 15 min. The anti-PC response from the S107/clan
III–encoded T15 set was measured by development with a satu-
rating concentration of the T15 clone–specific rat IgG2a, T139.2
(20; gift of Matthew Scharff, Albert Einstein College of Medi-
cine, New Hyde Park, NY), or with the T15-specific biotiny-
lated mouse IgG1, AB1-2 (21; gift of John Kearney, University of
Alabama at Birmingham, Birmingham, AL), with the recombi-
nant avian mAb, LJ-26, which has restricted recognition of clan
III products (including 7183, J606, S107, and DNA4) but not
clan I or II products (12). For quantitation, we used a calibration
curve of a T15 IgM mAb. The J558/clan I–encoded antibody re-
sponse to 
 
a
 
1–3 dextran was ascertained using an HRP–anti-
 
l
 
(Jackson ImmunoResearch Laboratories), and the IgM
 
l
 
, M104E,
was used in a standard curve.
To compare relative Fab-binding activity of the SpA forms,
100 
 
m
 
l aliquots of an mAb at fixed concentration were diluted in
1% BSA/PBS with 10 
 
m
 
g/ml of Fc (Jackson ImmunoResearch 
89
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Laboratories) and incubated for 4 h at room temperature with
one of the SpA forms at a range of concentrations; these were
later incubated for 1 h in wells coated with tetmDomD
 
9
 
. Plates
were developed with HRP-conjugated anti–mouse IgG or IgM
(Jackson ImmunoResearch Laboratories), as appropriate. To
evaluate relative Fc-binding activity, wells were coated with SpA,
and proteins were incubated with a fixed concentration of bio-
tinylated IgG Fc and later developed using streptavidin-alkaline
phosphatase (Kirkegaard & Perry Laboratories). Relative inhibi-
tion values were determined by comparison to a standard curve
of the protein without inhibitor.
 
Enzyme-linked Immunospot Assays.
 
The frequencies of Ig- and
specific antibody–secreting splenocytes and bone marrow were
quantitated as described previously (15). In parallel studies, wells
were coated with either goat affinity-purified anti–mouse IgM or
IgG (Jackson ImmunoResearch Laboratories), MSpA, control
protein antigens of OVA, HEL, or FCS, LJ-26 (12), AB1-2,
T139.2, Tc54.8 (Fig. 1), or isotype controls.
 
Flow Cytometry Analysis.
 
Adapting previously reported meth-
ods (15, 19, 22) to quantify the representation of SAg-susceptible
B cells, cells from a mononuclear cell scatter gate were evaluated.
For studies of T15i mice, we then gated on all allophycocyanin-
labeled anti-B220
 
1
 
 cells (clone RA3-6B2), and then evaluated
the representation of surface peridinin chlorophyll protein
(PerCP)- or PE-labeled anti-IgM
 
a
 
 (clone CS-1) to identify the
T15i transgene–expressing cells, and FITC-labeled anti–Mac-1
(clone M1/70) for peritoneal cells. For splenic studies, PerCP-
labeled anti-IgM
 
a
 
 and FITC-labeled anti-IgD (clone 11-26c.2a)
were used. For other studies of peritoneal B-1 cells, we gated on
IgD
 
low
 
B220
 
1
 
 cells, as described previously (22). The binding of
biotin-labeled anti–clan III (clone LJ-26; reference 12), detected
with PerCP-streptavidin, was then evaluated in B-1a and B-1b
subsets based on surface PE-labeled CD5 (clone 53-7.3). Staining
was performed in the presence of Fc block, with gates based on
staining with fluorochrome-labeled isotype controls. Replicate
samples were stained with FITC-labeled anti–mouse IgM (clone
11/410), or anti-
 
k
 
 and anti-
 
l
 
 to confirm equivalent Ig expres-
sion. Data were acquired using a FACSCalibur™ (Becton Dick-
inson) and analyzed with CellQUEST™ (Becton Dickinson) or
 
FlowJo software (Tree Star, Inc.). Dead cells were excluded based
on light scatter and propidium iodide uptake. All commercial re-
agents were obtained from BD PharMingen.
 
Reverse Transcription PCR/Southern Blot Surveys of V
 
H
 
 Family-
 
m
 
Expression.
 
As described previously (15), total RNA was isolated
from 4 
 
3
 
 10
 
7
 
 fresh splenic cells. After DNase treatment and phenol
chloroform extraction, 3 
 
m
 
g of total RNA was reverse transcribed.
For amplification, 1/10 of the first strand reaction product was
added to tubes containing 5 
 
m
 
l of 10
 
3
 
 PCR buffer (Boehringer),
5 
 
m
 
l of 25 mM MgCl
 
2
 
, 1 
 
m
 
l of 10 mM dNTP (Amersham Pharma-
cia Biotech), and 1 
 
m
 
l of each 50 mM primer solution (Operon).
Nuclease-free H
 
2
 
O was added to a final reaction volume of 49.5
 
m
 
l. Samples in triplicate were amplified using a hot start of 95
 
8
 
C for
3 min then 2 U of Taq Polymerase (Boehringer) was added; then
30 cycles of 95
 
8
 
C for 1 min, 60
 
8
 
C for 1 min, and 72
 
8
 
C for 1 min,
followed by a final 72
 
8
 
C for 5 min. 
 
b
 
-Actin cDNA content was
used to normalize total cDNA amounts added in the reactions.
Each of the V
 
H
 
 family–specific separate reactions used the same an-
tisense C
 
m
 
1
 
-derived primer (5
 
9
 
-ccc atg gcc acc aga ttc tta-3
 
9
 
) and
one of a previously described series of sense V
 
H
 
 FR1-derived oligo
primers (15, 23), and after electrophoretic separation on 2.5% aga-
rose gels and membrane transfer, blots were probed with V
 
H
 
 fam-
ily–specific plasmid probes (gift of Roy Riblet, Medical Biology
Institute, La Jolla, CA), with images analyzed as described (15).
 
Quantification of S107-
 
m
 
 Transcript Expression.
 
Applying the
Taqman™ (PerkinElmer) PCR-based 5
 
9
 
 nuclease system (24),
S107 mRNA transcripts were measured using the primers
S107FR1-sh (5
 
9
 
-AGC TTG GTA CAG CCT GGG-3
 
9
 
) and
mu3AS-sh (5
 
9
 
-ATG GCC ACC AGA TTC TTA-3
 
9
 
) and the in-
ternal S107-specific FR1 sequence probe (S107Frprob, 5
 
9
 
-TTC
TCT GAG WCT CTC CTG TGC AAC T-3
 
9
 
), and glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) transcripts (Perkin-
Elmer) were quantitated. Each 50-
 
m
 
l reaction tube contained 10
ng of cDNA, and a final concentration of 1
 
3
 
 Taqman™ Univer-
sal PCR Mix (PerkinElmer), 900 nM forward primers, 900 nM
reverse primers, and Taqman™ probe (450 nM for s107FR1-sh
probe or 200 nM for murine GAPDH). For
 
 
 
negative control
template, we used a V
 
H
 
12 cell line (NC1-A7; gift of Alan Whit-
more, University of North Carolina at Chapel Hill, Chapel Hill,
NC). For a calibration curve, 10 ng of S107.1-
 
m
 
–containing plas-
mid was added in six 1:10 serial dilutions to 10 ng of negative
control cDNA. Probes were 5
 
9
 
 labeled with a reporter (6-car-
boxy-fluorescein) and at the 3
 
9
 
 end with a quencher (6-carboxy-
tetramethyl-rhodamine). Amplification conditions were 95
 
8
 
C for
10 min, followed by 45 cycles of 95
 
8
 
C for 15 s and 60
 
8
 
C for 1
min. All samples were run in triplicate with data collected from
the ABI Prism 7700 (PerkinElmer). To compare the amount of
reporter dye with the quenching dye, we generated amplification
plots. The fluorescence threshold (
 
C
 
T
 
) was set to bisect the expo-
nential phase of fluorescence increase. Hence, with higher copy
number in a sample, fewer reaction cycles were required to attain
the threshold level of fluorescence, and the lower the designated
sample 
 
C
 
T
 
. To normalize the amount of RNA in each tube, tar-
get 
 
C
 
T
 
 values were normalized to the GAPDH 
 
C
 
T
 
.
 
Statistical Analysis.
 
Comparisons between different groups
used the nonparametric rank sum Wilcoxon and Mann-Whitney
one-tailed 
 
U 
 
test.
 
Results
Affinity/Avidity-dependent B Cell SAg Properties. In our
recent report, we demonstrated that neonatal treatment
Figure 1. A scheme of sets of murine VH genes and SAg reactivity. In
many strains, genes from clan I and clan II are the source of most of the
repertoire, whereas clan III represents a nonoverlapping set. Most clan III
products interact with the Fab-binding site of SpA and also with LJ-26, a
recombinant avian mAb. Each recognizes similar but nonidentical sets.
These also identify S107-encoded antibodies, including those expressing
the T15-specific VS107.1 rearrangement that generally display among the
highest levels of SpA-binding affinity.90 B Cell Superantigen–induced “Hole” in the B-1 Repertoire
with a chemically modified form of SpA (MSpA) induced a
persistent suppression of MSpA-reactive splenic ISCs (15).
To better define the features responsible for B cell immu-
nomodulatory properties of this natural bacterial toxin, we
assembled a panel of different forms of SpA, and the Ig-
binding properties of these proteins were compared in di-
rect binding and inhibition studies with human and murine
mAbs. In a representative study (Fig. 2), all of these pro-
teins displayed the same clan III–specific Fab-binding spec-
ificity, although relative affinity/avidity varied greatly (Ta-
ble I). Native SpA displayed the strongest Fab-binding
activity, whereas MSpA exhibited about fivefold weaker
activity. Compared with native SpA, the monomeric do-
main D9 of SpA, which is capable of simultaneously bind-
ing a VH3 Fab and an Fcg molecule via distinct sites (5),
exhibited z5,000-fold weaker Fab-binding activity. By in-
troduction of the L17D and I31A mutations that are re-
ported to ablate Fc-binding activity (17), a genetic mutant
domain D9 (mDD9) was generated and oligomeric forms
were also engineered. Although not anticipated, the mu-
tant dimeric and tetrameric mutant SpA forms, dimDD9
and tetmDD9, exhibited z2,000–5,000-fold weaker Fab-
binding activity than native SpA. In separate studies, the
MSpA and mutant SpA forms were devoid of detectable
Fcg activity, whereas the greatest binding activity was dis-
played by SpA, and by comparison the domain D mono-
mer had z500-fold weaker inhibitory activity (not shown).
Fab-binding Avidity Determines Level of Immunosuppres-
sion. To investigate the in vivo biologic activities of dif-
ferent proteins, mice were treated during the first 2 wk of
life and then evaluated months later. In general, neonatal
treatment with SpA or control protein antigen resulted in a
lasting increase in the overall frequency of splenic constitu-
tive ISCs (Fig. 3 A; reference 15). To evaluate whether
treatment altered the representation of ISCs reactive with
the clan III–specific Fab-binding site of SpA (i.e., SAg-
reactive ISCs), we ascertained the frequencies of cells pro-
ducing IgM that bind to MSpA-coated wells (15) and
found that in naive adult mice, 12.5 6 0.7% (mean 6
SEM) of splenic ISCs were SAg reactive and this propor-
tion was not altered by prior treatment with a control pro-
tein antigen (HEL, 12.3 6 1.1%; Fig. 3 A) (15). Treatment
with the tetrameric mutant SpA form, which has weak
Fab-binding activity and no Fc-binding activity, induced a
minor decrease (10.3 6 0.7%) in the representation of
SAg-reactive ISCs that was not significantly less than in
control groups (P 5 0.095). By contrast, treatment with
the domain D9 monomer induced a significant level of in-
hibition (7.9 6 0.02%, P 5 0.03). A greater level of sup-
pression was induced by MSpA, which has relatively strong
Fab-binding activity and no Fc-binding activity (6.25 6
0.4%, P , 0.001). However, the greatest suppression was
detected in mice treated with native SpA, which has the
strongest Fab-binding activity (2.8 6 0.4%, P , 0.004). Es-
sentially the same patterns of suppressive activity were also
detected in bone marrow ISCs, where the effects in the
MSpA- and SpA-treated groups were similar (Fig. 3 B). A
similar effect was also demonstrated for cells in the perito-
neal cavity, the treatment site (not shown). Even though
total IgM levels were generally increased compared with
naive mice (not shown), SpA treatment of neonatal mice
also induced a decrease in the levels of MSpA-binding cir-
culating IgM (15). Notably, a total dose of only 50 mg of
MSpA often induced a similar level of suppression, but the
responses of mice within this treatment group were more
heterogeneous (not shown). Hence, the level of supra-
clonal suppression of SAg-reactive ISCs directly correlated
with the relative Fab-binding affinity and not the Fc-bind-
ing activity.
Adult Mice Are Also Susceptible to SAg-induced Immunosup-
pression. To ascertain whether adult mice are also affected
by SpA treatment, 7-wk-old BALB/c mice were given
proportionately larger doses and evaluated 1 mo later. In
Figure 2. Recombinant forms of SpA display a broad range of Fab-
binding avidities. The relative Fab-binding activities of five different
forms of SpA were compared in inhibition immunoassays of the binding
of an S107-encoded IgG in solution to wells coated with an SpA variant.
In these studies, the activity of native SpA is compared with a form of
SpA created by chemical modification (MSpA), an SpA monomer, do-
main D (DD9), and dimeric (dimtetDD9) and tetrameric (tetmDD9) forms
of domain D9, which include two site-specific mutations that remove Fc-
binding activity.
Table I. Relative Activities of SpA Forms
SpA form MW
No. of
domains Fab-binding* Fc-binding
kD M M
SpA Native 42 5 2 3 1026 4 3 1027
MSpA Iodinated 42 5 1 3 1025 ND‡
DD9 Native 11 1 1 3 1022 2 3 1024
DimDD9 L17D I31A 24 2 1 3 1022 ND
TetmDD9 L17D I31A 37 4 5 3 1023 ND
MW, molecular mass.
*Relative activities based on 50% inhibition studies in a solution phase
enzyme immunoassay.
‡Not detected. Detection limits in these assays were z5 3 1021 M.91 Silverman et al.
these treated mice, the frequency of total splenic ISCs was
not affected, whereas SAg-reactive splenic ISCs were sig-
nificantly reduced by treatment with MSpA (4.81 6
0.95%, P , 0.001) or SpA (3.41 6 0.039%, P , 0.0005)
compared with control groups (Fig. 3 C). Similar suppres-
sive effects were also found on constitutive ISCs in the
bone marrow (Fig. 3 D).
T Lymphocytes Are Not Required for SAg-induced B Cell
Suppression. To investigate whether T lymphocytes play a
critical role in SpA-induced B cell suppression, we evalu-
ated the effect of neonatal treatment on mice with ho-
mozygous deficiencies in both TCR b and d chains
(TCR-b2/2d2/2), which are devoid of mature T cells (25,
26). Akin to the control C57BL/6 groups, neonatal treat-
ment of T cell–deficient mice with a protein antigen also
resulted in increased overall levels of splenic ISCs, while
these mice were also susceptible to SpA-induced selective
decreases in the frequency and relative representation of
SAg-reactive ISCs in the spleen (Fig. 3 E) and bone mar-
row (Fig. 3 F). Compared with control groups, SpA treat-
ment reduced by 35% the proportion of clan III–expressing
splenic ISCs (P 5 0.007; Fig. 3 E), identified by a broadly
Figure 3. The level of loss of
SAg-reactive ISCs in bone mar-
row and spleen after neonatal or
adult treatment with SpA. Level
of suppression correlates with
avidity of Fab-binding activity
and does not require T cells.
BALB/c mice treated as (A and
B) neonates or as (C and D)
adults, or (E and F) neonatally
treated TCR-b2/2d2/2 or con-
trol C57BL/6 mice, received in-
traperitoneal injections of saline
(Naive), a control antigen
(HEL), a genetic mutant tet-
rameric form of SpA (tetmDD9),
an SpA monomer (DD9), a
chemically modified form of SpA
(MSpA), or native SpA. The fre-
quencies of IgM-specific ISCs in
the spleen (A, C, and E) and
bone marrow (B, D, and F) were
quantitated 2–5 mo later by en-
zyme-linked immunospot assay.
Replicate wells coated with anti-
IgM established the total fre-
quency of IgM-ISCs (left); with
MSpA determined the frequency
of ISCs that interact with the
Fab-binding site of SpA (mid-
dle); or with a control antigen
established that the frequency of
ISCs with nonspecific binding
activity was ,10/106 total cells
(not shown). For each mouse,
the relative proportion of ISCs
with SAg reactivity was deter-
mined by dividing the frequency
of MSpA-reactive IgM-ISCs by
the frequency for total ISCs
(right). The frequency of PC-
specific ISCs was below the lim-
its of detection (not shown; ref-
erence 59). 1, mean values for
each group. For comparisons to
control protein-treated groups,
significant values are indicated as
follows for SpA-treated groups:
*P , 0.05; **P , 0.01; ***P ,
0.005;  ****P  ,  0.001. Values
represent the frequency of each
type of IgM-secreting cell per
million mononuclear cells, or the
relative percentage of these IgM-
secreting cells among all IgM-
secreting cells (%), as indicated.92 B Cell Superantigen–induced “Hole” in the B-1 Repertoire
reactive clan III Ig–specific marker (LJ-26 antibody) (12).
The T15 B cell clonal set represents only a small compo-
nent of VH clan III/S107–expressing cells, and using a
VHT15-specific marker (Tc68) we found that in these
treated mice the representation among ISCs of these prod-
ucts was reduced by 76% (P 5 0.0002) in the spleen (Fig. 3
E) and by 82% in bone marrow (P 5 0.026; Fig. 3 F).
Compared with control groups, levels of circulating natural
Ig-bearing T15-specific idiotypic markers, which included
IgM, IgG2b, and IgG3 responses, were each found to be
significantly reduced (not shown). These results document
that SpA-induced suppression is mediated via a B cell–tar-
geted mechanism affecting certain S107-expressing B cells,
which is not dependent on T cell influences.
SAg Induces a Selective VH Family–targeted Deficit in the Ex-
pressed Ig Repertoire. To ascertain whether these defects in
SAg-reactive ISCs and circulating IgM reflect losses re-
stricted to VH family–defined supraclonal B cell sets, reverse
transcription (RT)-PCR/Southern blots were performed.
Compared with naive age-matched mice, akin to the find-
ing of increased IgM levels, we found that treatment with a
control protein induced a nonspecific increase in transcript
expression of m rearrangements of each of seven different
VH families studied (Fig. 4 A). Significantly, MSpA or SpA
treatment induced a selective expression deficit of only the
clan III/S107 family (Fig. 4 A). A similar selective suppres-
sion of VH S107 transcript expression was also documented
after SpA treatment of adult mice (not shown).
To quantitate the deficit, we used a real-time PCR–
based assay system, which demonstrated that neonatal treat-
ment with MSpA or SpA significantly reduced splenic
S107-m transcript expression levels by a mean 97.7 and
98.6% (P , 0.001) compared with control age-matched
mice, respectively (Fig. 4 B). Notably, in many of these
SAg-treated mice, S107 transcript levels were actually or-
ders of magnitude lower than the groups’ mean values, in-
dicating much greater levels of suppression. Furthermore,
for mice treated as adults and evaluated 1 mo later, SpA ex-
posure also induced a mean 90% reduction in S107-m tran-
script expression (P , 0.001). In addition, after treatment
with MSpA, five of seven mice displayed .90% reductions
of S107-m transcript expression (not shown). Hence, in
vivo exposure to SpA targets a supraclonal B cell set, result-
ing in a nearly complete loss of S107 transcript expression
that appears to be linked to the selective loss of certain clan
III–constitutive antibody-forming cells that are a source of
natural antibodies.
SAg Exposure Alters the Natural Antibody Repertoire and In-
duces Tolerance to PC. To evaluate the consequences of
SAg exposure on natural antibodies of defined clonal ori-
gin, we measured the levels of antibodies to PC, an immu-
nodominant moiety present in many microbial pathogens
(16). In many murine strains, antibodies to PC predomi-
nantly derive from T15 B cells that employ a specific pair-
ing of canonical VH and Vk rearrangements (23, 27; Fig. 1).
Notably, these T15 clones are represented at high fre-
quency in the B-1 pool without prior immune exposure
even in germ-free mice (27, 28), and provide defense from
systemic infection from virulent pneumococci (29) and Sal-
monella typhi (30). Only higher avidity Fab-binding forms
(e.g., MSpA or SpA) inhibited levels of PC-specific natural
antibodies, including those from the T15 clone (Fig. 5 A).
In contrast, levels of natural antibodies to a1–3 dextran,
which arise from a separate B-1 clonal set expressing a de-
fined clan I/J558 rearrangement, were increased in each of
the treatment groups (Fig. 5 B), reflecting the nonspecific
increase of total circulating IgM (not shown). Hence, SpA
exposure selectively suppressed a VH-targeted set of anti-
gen-specific natural antibodies.
To assess the impact of SAg exposure on the immune
competence of the host, mice in different neonatal treat-
ment groups were challenged with dextran and PC immu-
Figure 4. SAg-treated mice display a loss of S107 VH family–specific m
rearrangements in the spleen. (A) RT-PCR/Southern blot surveys of
VH-m transcript expression were performed using splenic RNA. Differ-
ent VH FR1–specific primers were used to amply transcripts from fami-
lies of clan I (J558), clan II (Q52), and clan III (S107, J606, and 7183),
and results for several major VH families are shown. Results for BALB/c
mice treated as neonates are shown, but similar results were also obtained
for mice treated as adults then evaluated 1 mo later (not shown). Rela-
tive b-actin content is demonstrated by staining with Sybr Green Dye II
(Molecular Probes). For each treatment group, signals for fivefold serial
dilutions of splenic cDNA from two different mice are demonstrated.
Nonspecific posttreatment increases were also documented for m tran-
scripts of the Vgam3 and X24 families (not shown). (B) Quantitative as-
says of splenic S107-m transcripts for groups that received neonatal or
adult treatment are displayed. Relative S107 CT values were calculated
using the untreated group as the denominator. Replicate values displayed
,10% coefficient of variation (not shown). 1, mean values for each
group. For comparisons with control protein-treated groups, significance
is indicated as follows: ****P , 0.001.93 Silverman et al.
nogens that induce TI-2 responses. Compared with the
vigorous responses in naive or control protein-treated
groups, all of the mice neonatally treated with MSpA or
SpA were tolerant to challenge with S. pneumoniae extract,
whereas the mice treated with the domain D9 monomer of
SpA displayed highly heterogeneous anti-PC responses
(Fig. 6 A). In other challenged groups, mice treated as neo-
nates with SpA were also nonresponsive to the PC-contain-
ing purified C-PS TI-2 immunogen (not shown), and were
also tolerant to the T cell–dependent PC immunogen PC-
KLH (Fig. 6 B) that also recruits a response dominated by
T15 B cell clone(s) (31). Treatment of adult mice with SpA
induced the same selective tolerance to the PC-containing
pneumococcal immunogen (Fig. 6 C). Therefore, SAg
treatment induces tolerance in an antigen-specific response
requiring clan III/S107–expressing B cell clonal sets; in the
absence of this response, other clonal sets are not recruited
into this response, whereas a response requiring an clan
I/J558–expressing B cells is unaffected (Fig. 6, A and C).
SpA Induces a Loss of Detectable Clan III–expressing B-1
Cells in the Peritoneal Cavity. To consider the cellular
mechanisms responsible for SpA-induced defects, we have
evaluated T15i transgenic “knockin” mice that have B cells
expressing the canonical T15/S107 VH rearrangement. In
heterozygotic mice, clonal representation of B cells can be
readily tracked, as B cells expressing endogenous VH regions
bear the IgMb allotype, whereas expression of the VHT15
transgene is linked to the IgMa allotype. Confirming their
earlier characterization (32), in these mice most peritoneal
VHT15-expressing B cells, which coexpress diverse endoge-
Figure 5. SpA or MSpA induces persistent loss of natural IgM anti-PC
antibodies, whereas natural IgM anti-a1–3 dextran antibodies are non-
specifically increased. Neonatal BALB/c mice were treated with control
proteins or different forms of SpA for the first 2 wk of life, and natural
IgM antibody levels were quantitated 3–5 mo later. For groups of four
mice, serial dilutions of antibody reactivities in ELISA are indicated with
mean 6 SEM.
Figure 6. Neonatal or adult treatment with SpA causes a persistent toler-
ance to PC-containing immunogens. Postimmune responses were mea-
sured 10 d after challenge of 3-mo-old mice (A) with pronase-treated ex-
tract of R36A pneumococcal bacteria and B1355 dextran in CFA, and (B)
with PC-KLH emulsified in CFA. (C) Adult BALB/c mice were treated
with SpA, and then challenged 7 d later. Detection of anti-PC responses
used the T15 clone–specific AB1-2 antibody, which recognizes an idiotope
requiring coexpression of both the T15 VH and VL regions (reference 21),
and also the clan III–restricted avian mAb, LJ-26 (reference 12). Groups are
indicated by the protein with which they were conditioned and subse-
quently challenged, with comparison to control groups of naive mice chal-
lenged with R36A and dextran in CFA (Naive/R36A Dex), and to naive
mice that received CFA alone (Naive/CFA). Values are relative antibody
units per milliliter. *P , 0.05; **P , 0.01; ***P , 0.005; ****P , 0.001.94 B Cell Superantigen–induced “Hole” in the B-1 Repertoire
nous L chains, bear the phenotype of B-1b cells (i.e.,
B220lowIgDlowMac-11CD52). Clarifying our previously re-
ported findings in BALB/c mice, 1 d after completion of
neonatal SpA treatment, heterozygous mice exhibited a
.90% reduction of VHT15 transgene–expressing splenic B
cells (not shown). Furthermore, treatment of adult 6-wk-
old mice with a single 0.5-mg dose of SpA also induced an
acute selective loss of .60% of VHT15-expressing splenic
and peritoneal B cells when evaluated 1 d later (not shown).
To evaluate the clonal representation associated with
long-lasting functional defects, we studied T15i heterozy-
gous mice months after the last SpA exposure. At these late
time points, there were no major differences in the repre-
sentation of transgene-expressing splenic conventional B
cells (IgDhiB2201) (Fig. 7 B), presumably because these B
cells are continually replenished from the bone marrow.
However, in the peritoneal cavity, a major anatomic resi-
dence of B-1 cells, neonatal SpA treatment resulted in a
highly significant mean 78% reduction (P 5 0.0006) in the
frequency of VHT15 transgene–expressing peritoneal B-1
cells (Mac-11B2201) (7.9 6 1.1%, n 5 7) compared with
control treated mice (36.5 6 3.2%, n 5 6) (Fig. 7 A). Using
the clan III (LJ-26) marker, comparable losses of transgene-
expressing B-1 cell populations were also demonstrated in
the peritoneum but not the spleen (not shown). We also
demonstrated similar findings in studies of adult TCR-defi-
cient mice with polyclonal endogenous B cell populations.
In the T cell–deficient mice that had received neonatal SpA
treatment, the representation of clan III–expressing perito-
neal B-1a (LJ-261IgDlowB2201CD51) cells was signifi-
cantly reduced (8.1 6 0.49%, n 5 4, P , 0.016), represent-
ing a mean 30% reduction, compared with naive (11.5 6
0.36%) or control treated mice (10.3 6 0.52%). Similar
significant losses were also demonstrated in the clan III–
expressing B-1b (LJ-261IgDlowB2201CD52) cells of SpA-
treated mice (6.8 6 0.48%, P , 0.015) compared with
naive (9.7 6 0.14%) and control treated mice (9.75 6 0.65%)
(Fig. 7 C). In contrast, the representation of conventional
splenic B cells in these mice was not significantly affected
(not shown). These findings demonstrate that a limited in-
terval of exposure to SpA can induce a long-lasting clonal
loss of clan III/S107–expressing peritoneal B-1 cells.
Discussion
We have demonstrated that in vivo exposure to staphy-
lococcal protein A, a model B cell SAg, results in a selective
targeting and immunosuppression of a supraclonal set of B
lymphocytes that express VH clan III antibody genes, and
both neonatal and mature mice are susceptible. In general,
the magnitude of the induced B cell defect correlated with
the relative avidity of Fab-binding interaction of the SAg.
While the structural basis of this SAg–BCR interaction is
no doubt distinct from those associated with binding of
conventional antigens, these findings are consistent with
earlier observations in which high affinity ligands are most
effective at inducing B cell tolerance in classical models
(33) and in transgenic Ig models (34, 35).
In surveys of the murine antibodies, many genes from
clan III–related VH families commonly encode for binding
of this prototypic bacterial B cell SAg (13, 14), but certain
of these genes, especially those from the S107 family, gen-
Figure 7. Persistent clonal loss of VHT15 and clan III–expressing peri-
toneal B-1 cells. In each multigroup study, naive, SpA- or control pro-
tein-treated mice were included, with comparisons to naive BALB/c and
C57BL/6 mice. Mice were treated as neonates, and then evaluated 7–21
wk later in microfluorimetric assays. Representative results from studies of
T15i mice (A) peritoneal cavity and (B) splenic mononuclear cells are dis-
played. For these analyses, gates were set so that ,0.8% of C57BL/6
(IgMb)B2201 cells were reactive with the IgMa-specific reagent. Repre-
sentative results are shown from the (C) peritoneal cells of matched
groups of TCR-b2/2d2/2 mice, evaluated 16 wk after the last exposure.
In these results, control mice were treated with HEL, with equivalent
findings in control b-galactosidase–treated mice (not shown). For each B
cell subset, the IgMa or LJ-26 reactivity was used to derive the percent-
ages representative of clan VHIII–expressing B cells.95 Silverman et al.
erally encode for antibodies with greater SpA binding ac-
tivity (14). These findings parallel data from earlier studies
of phage-display antibody libraries, in which SpA preferen-
tially selected for phagemid clones expressing certain hu-
man germline VH3 genes that conveyed greater SpA bind-
ing activity (5, 8). In the current studies, we have now
demonstrated that in vivo exposure to SpA can induce a
nearly complete loss of constitutively expressed splenic
S107-m transcripts and natural IgM, including anti-PC an-
tibodies. In view of the cumulative data, we can only inter-
pret the loss of these S107-expressing B cell clones as due,
at least in part, to their higher binding affinity for SpA.
The susceptibility of T cell–deficient mice to SAg-induced
immune defects indicates that this process, which is asso-
ciated with long-lasting clonal loss, does not have an
obligatory T cell dependence. In fact, induced PC-specific
tolerance persists in the presence of SpA-specific T cells
(15). Hence, SAg-induced tolerance has features that ap-
pear distinct from experimental models of B cell tolerance
in which the unavailability of antigen-specific T cells is a
primary determinant in whether B cell interactions with
nominal antigen result in clonal anergy and/or deletion
(36, 37).
The capacity to induce a persistent “hole” in the B cell
repertoire is not unique to SpA, as similar outcomes have
also been previously reported upon treatment with certain
specific B cell ligands/antigens, or with antiidiotypic anti-
bodies that act as their surrogates (38). However, we know
that in naive mice, PC-specific antibody-forming cells nor-
mally represent only an estimated 1/50,000 splenocytes
(39), indicating that PC-specific B cells represent only a
limited component of the large supraclonal set affected by
SAg exposure. Hence, the distinction of the SpA response
derives in part from the much larger scale of the induced
supraclonal defect. In addition, the immunological proper-
ties of SpA are also special, as this naturally occurring “tol-
erizing agent” affects host responses to other immunogens
by virtue of its ability to interact with supraclonal sets via
VH family–specific interactions (i.e., it has superantigenic
properties).
Our earlier surveys identified two distinct temporal
phases in BALB/c mice during the response to neonatal
treatment with this B cell SAg. Throughout both early and
late phases, suppression of levels of SAg-reactive IgM was a
consistent finding (15), whereas the late phase response, be-
ginning at z6 wk of life, was distinguished by the acquisi-
tion of SpA-specific T cell responsiveness and the induc-
tion of SAg-specific IgG1 antibody production. In the
current studies, T cell–deficient mice were also found to be
sensitive to the induced B cell supraclonal suppression, but
the features characteristic of the late phase of the response
were absent in these mice. This late phase T cell–depen-
dent response likely involves conventional (B-2) lympho-
cytes in germinal center–type reactions in secondary lym-
phoid tissue that elaborate clonally focussed MSpA-reactive
IgG1 antibody responses (Silverman, G.J., manuscript in
preparation). Therefore, because these IgG1 responses from
conventional B cells can reconstitute in BALB/c mice, our
data indicate that it is the effects of this bacterial toxin on a
separate B cell pool that is responsible for the persistent in-
duced defects in anti-PC responses and natural antibody
production.
Several compelling pieces of evidence implicate the tar-
geting of clones within the B-1 pool as the origin of the
long-lasting immunological defects. Most relevant, B-1
cells are believed to be the source of constitutively pro-
duced natural IgM antibodies that provide the primary de-
fense against many common microbial pathogens (40, 41).
Moreover, the susceptible set includes T15 B cells, the
source of S107-encoded anti-PC antibodies that dominate
these natural IgM and postimmunization protective re-
sponses, which adoptive transfer studies have rigorously
demonstrated reside predominantly, if not solely, within
the B-1 pool (42, 43). We found that SAg exposure re-
sulted in a near complete loss of splenic S107-m transcripts,
but these findings, from RNA-based assays, are greatly in-
fluenced by the representation of antibody-forming cells
that contain 100–1,000-fold greater amounts of antibody-
specific transcripts than resting B cells. Hence, the dramatic
reductions in S107-m transcript levels undoubtedly reflect
the loss of an SAg-reactive set of constitutive ISCs that de-
rive from B-1 cells to produce natural antibodies.
The special immunobiology of B-1 cells explains their
susceptibility to the persistent VH-targeted effects of SpA.
For the developing murine B-1 pool, entry of newly gen-
erated lymphocytes is reportedly complete by the end of
the neonatal period, and thereafter these B cells are self-sus-
taining and cannot be replenished by the lymphoneogene-
sis that perpetually supplements the conventional (B-2)
compartment in the adult (44–46). Also relevant, compared
with splenic follicular B cells, adult peritoneal B-1 cells are
poor responders to in vitro stimulation with anti-IgM, an
experimental surrogate for a BCR signal. In fact, BCR-
mediated apoptosis is a common outcome of high level an-
tigenic stimulation of these extrafollicular cells (47, 48).
Strong in vivo cross-linking of cell surface Igs has also been
reported to induce apoptotic death of mature B cells in the
peritoneal cavity (48). Presumably, these features of B-1
cells are also responsible for the persistent clonal loss that
results from instillation of IgM allotype–specific antibody
into allotype heterozygotic mice (49). Based on these ob-
servations, it is predictable that even a limited exposure to a
potent natural BCR-targeted agent would induce a supra-
clonal hole in the B-1 repertoire that would persist, likely
indefinitely. In earlier studies, we demonstrated a transient
supraclonal deletion in the spleen and bone marrow imme-
diately after SAg treatment (15); however, the clonal repre-
sentation at these sites later normalized, presumably because
of replenishment of conventional B cells from the central
compartment. Consistent with this hypothesis, in surveys
of splenic VH-d rearrangements that are representative of
mature naive conventional follicular B cells (i.e., sIgDhi),
we did not detect a lasting SAg-induced supraclonal defect
(Silverman, G.J., manuscript in preparation). These find-
ings contrast with the persistent loss of VHS107-m tran-
scripts characterized in the current studies, which correlates96 B Cell Superantigen–induced “Hole” in the B-1 Repertoire
with the supraclonal loss of splenic constitutive ISCs that
have been linked to the B-1 pool. Hence, we believe that
the lasting SpA-induced loss of SAg-reactive clan III–
derived peritoneal B-1 cells reflects their special vulnerabil-
ity for the induction of persistent clonal defects by this bac-
terial Fab-binding protein.
B-1 cells are associated with a distinct repertoire that in-
cludes well-defined clonal sets that produce natural anti-
bodies responsible for housekeeping and antimicrobial
functions. From lessons first appreciated for the T15 clone,
it appears that the binding specificities of B-1 cells com-
monly derive from canonical antibody gene rearrangements
formed in primary sequence-directed splicing events (23,
50, 51) and are subsequently subject to ligand-mediated
clonal selection (52); hence, B-1 cells have been postulated
to convey a repertoire naturally selected during the evolu-
tion of the adaptive immune system (53). From this view-
point, targeting of host clan III B cells, especially those pro-
viding natural immune defenses (29, 41), may provide a
great advantage to a pathogen. Clan III genes are expressed
in the immune systems of phylogenetically distant species as
far back as elasmobranchs, and in certain species these anti-
body genes are the earliest expressed during development
(11). In particular, clan III VH families and SpA-binding ac-
tivity are highly represented in mammalian immune sys-
tems (12), and in humans .30% of B cells are targeted by
SpA (19). Moreover, the current findings, which elucidate
the immunological properties of SpA, should also help us
to understand the effects of other postulated B cell SAgs
(54–56). In particular, our findings may provide insight
into how the SAg properties of HIV-1–associated retroviral
products may contribute to a predisposition to certain in-
fections (57), especially the otherwise inexplicably high fre-
quency of pneumococcal sepsis (58).
In summary, our findings indicate that staphylococci
produce a toxin that can impair host defenses through ef-
fects on B lymphocytes, for which B-1 cells have special
vulnerability. These interactions are mediated by an un-
conventional binding site on clan III–associated VH region
framework subdomains that have been highly conserved in
evolution (10). From these findings, we speculate that this
common pathogen has developed a toxin with B cell SAg
properties to exploit a primordial Achilles heel in the im-
mune system.
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